RESUMEN
OBJECTIVE: To evaluate the clinical efficacy of decitabine combined with arsenious acid in the treatment of patients with higher-risk myelodysplastic syndromes(MDS) and chronic myelomonocytic leukemia(CMML). METHODS: Totally 39 patients with MDS and 8 patients with CMML received the treatment of decitabine and arsenious acid from April 2016 to December 2018. Decitabine [20 mg/(m~2·d)] and arsenious acid [0.15 mg/(m~2·d)] were administered intravenously for 5 consecutive days every 4-6 weeks. Patients who achieved complete or partial remission entered into the consolidation cycle. Efficacy and influencing factor were analyzed. RESULTS: Clinical response were observed in 31 patients after a median of 2 courses(ranging 1-12) of treatment. The overall response rate(ORR) was 66.0%. The median duration of response was 16 weeks(ranging 2-52 weeks). There were 8 cases(17.0%) of complete remission(CR), 10 cases(21.3%) of partial remission(PR),12 cases(25.5%) of hematological improvement(HI), 1 case(2.1%) of marrow complete remission(mCR), 8 cases(17.0%) of stable disease(SD), and 1 case(2.1%) of progressive disease(PD). By next generation sequencing, 25 genes mutated with 70 times in 33 cases. The mutation frequency of epigenetic regulators(57.6%) was higher than splicing factors(33.5%), transcription factors and kinase signaling(54.5%),and TP53(21.2%)(P<0.01). There was no significant difference in response rates among these patients(47.4%, 54.5%, 50.0% and85.7%, P=0.977). Gene mutation frequency(VAF) of patients who responded to the regimen declined significantly(16.67% vs. 10.26%,P=0.014). CONCLUSION: Decitabine combined with arsenious acid has significant effect in the treatment of patients with higher-risk MDS and CMML and is well-tolerated. Gene mutation test results by next generation sequencing might be related to clinical response.
RESUMEN
Objective To analyze the characteristics of drug resistance in tuberculosis patients in Shaoxing and provide scientific basis for prevention and control of tuberculosis.Methods All the sputum smear -positive specimens from tuberculosis patients in Shaoxing tuberculosis designated hospitals from 2010 to June 2013 had been done by susceptibility test using susceptibility Jensen medium.The situation of drug resistance in patients with pulmonary tuberculosis was analysed.Results In the 607 sputum culture -positive cases,the total resistance rate was 20.26%;the multi -drug resistance rate was 12.85%.The resistance rate in descending order was INH,RFP,SM and EMB.In new cases,the total resistance rate was 13.09%,and the multi-drug resistance rate was 5.73%;in retreated cases,the total resistance rate was 50.00%,and the multi-drug resistance rate was 42.37%.Conclusion In Shaoxing City,the total resistance rate of tuberculosis is consistent with the national average level,but the epidemic of MDR-TB is still very serious.